History
Menarini Biomarkers Singapore (MBS) was created in 2014 by Menarini Asia Pacific in Singapore and is fully owned by Menarini Group the biggest Italian Pharma Company with annual revenue of 3.8 Billion Euro (2021). Menarini Group, which was founded in 1886, has over 17,000 employees working in more than 130 countries.
The initial mission of MBS was to identify, develop and validate new biomarkers on circulating human cells for applications in diagnostics. From liquid biopsies, circulating cells such as CFC (circulating fetal cells) or CTC (circulating tumor cells) were captured by specific antibodies developed against novel targets and conjugated to FerroFluid (Menarini-Cell Search Technology) and further selected by sorting as single cells for molecular analysis.
Using this approach, MBS has been able to identify biomarkers on circulating trophoblasts from pregnant women and has established a platform to capture them. This technology will transform prenatal diagnostics.
Mission
MBS aspires to launch a leading and innovative Platform for a non-invasive Cell-Based test suitable for the entire pregnant population. This will help clinicians, at a worldwide level, manage accurate prenatal testing and allow personalized treatments in addressing genetic disorders prenatally.
Stephen Phua, MD
Luigi Ricciardi
Thomas Musci, M.D.
Paola Castagoli, PhD
Francesca Romana Grati, Ph.D. , ErCLG
Anna Doffini, PhD